



Eurofins Central Laboratory Expands U.S. Lab Operations to Eurofins Campus in Lancaster, PA

Lancaster, PA – 10 June 2014

Eurofins Central Laboratory is pleased to announce that it has achieved an important strategic milestone with the expansion and relocation of its U.S. Central Laboratory Operations to the 330,000 square foot Eurofins Pharma Services campus in Lancaster, PA. The consolidation of the Central Laboratory into the Lancaster Laboratories campus, combined with the recently announced acquisitions of leading bioanalytical, discovery, genomic and diagnostic laboratories in the US, positions Eurofins as a leading full service laboratory provider to the pharmaceutical and biotech industries. This purpose built Central Laboratory is essential to the Eurofins Central Laboratory global footprint of wholly-owned laboratory facilities in the United States, Europe, Asia and China.

Dr. Charles J. DiComo, Vice President & General Manager, U.S. & Global Laboratory Operations, explains: "The Central Laboratory in Lancaster is fully harmonized and seamlessly aligned with our other Eurofins Central Laboratories. All laboratory equipment, analytical methods, standard operating procedures and quality standards are identical across laboratories to support clinical trials being conducted across regions by our clients. Operating in line with both GLP and GCP standards, and with a strong expertise in biomarker analysis, we are positioning ourselves to become the first-choice Central Laboratory for our pharmaceutical sponsors."

Successfully operational since early April, the Eurofins Central Laboratory in Lancaster offers a full package of safety and esoteric testing. Furthermore, this location houses the Microbiology Center of Excellence for Eurofins Central Laboratory. The facility is accredited by the Pennsylvania Department of Health, CAP, CLIA and NGSP Level I.

Elena Logan, Global Vice President Sales & Marketing, remarks: "The expansion of our Central Laboratory services on the Lancaster campus signifies the importance of this business within the portfolio of offerings of Eurofins Pharma Services. The Central Laboratory is core to the integration of our other laboratory services and as such, we continue to make significant investments in the business to ensure customers receive first class service and optimal delivery of results to support key decision making during and as a result of the clinical trials being run with Eurofins."

For more information about Eurofins, please visit www.eurofinsus.com or contact:

Charles DiComo
Vice President, Eurofins Central Laboratory
Tel.: +1 717 656 2300
Email: clinicaltrials@eurofins.com

Notes for the editor:**Eurofins – a global leader in bio-analysis**

Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agrosience, genomics, discovery pharmacology and central laboratory services.

With over 15,000 staff in more than 190 laboratories across 36 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

About Eurofins Central Laboratory

Reliable, high quality laboratory data is pivotal to the success of clinical trials. Since laboratory testing is our sole focus, we go above and beyond to provide an array of services to ensure that any clinical trial sample is collected, transported, managed, analyzed, reported and stored to meet the objectives and purpose of your study. We are dedicated to providing the most cost effective and efficient solutions to pharmaceutical and biotech companies, and CROs alike.

Eurofins Central Laboratory supports its customers across its wholly-owned CAP accredited laboratory facilities in the United States, Europe and Asia. Our harmonized laboratories operate as one. All of our laboratories are connected to one global LIMS and are using the same global standard operating procedures and global reference ranges through the deployment of uniform instruments, reagents, and analytical methods to provide one global data set for submission to health authorities worldwide.

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantee can be made as to their validity.